U. Müller-Ladner

U. Müller-Ladner, S. Rehart, E. Neumann, 2021, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models.

U. Müller-Ladner, S. Gay, E. Neumann, 2005, Arthritis and rheumatism.

Chapter 79 – Systemic Sclerosis

U. Müller-Ladner, S. Lambova, 2013 .

Pulmonary arterial hypertension in systemic sclerosis.

U. Müller-Ladner, S. Lambova, 2010, Autoimmunity Reviews.

Case report of severe PCR-confirmed COVID-19 myocarditis in a European patient manifesting in mid January 2020

U. Müller-Ladner, C. Hamm, A. Rolf, 2020, European heart journal. Case reports.

Genomic organization, promoter, amino acid sequence, chromosomal localization, and expression of the human gene for CORS-26 (collagenous repeat-containing sequence of 26-kDa protein).

U. Müller-Ladner, J. Schölmerich, H. Herfarth, 2003, Biochimica et biophysica acta.

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

H. Heinzl, U. Müller-Ladner, C. Denton, 2013, Annals of the rheumatic diseases.

Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement.

A. Günther, U. Müller-Ladner, S. Gay, 2019, Cytokine.

Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis

Erika Salvi, Mohamad Saad, Eric Hachulla, 2011, PLoS genetics.

TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients

H. Wichmann, M. Humbert, M. Müller-Nurasyid, 2012, Annals of the rheumatic diseases.

Disease-Specific Effects of Matrix and Growth Factors on Adhesion and Migration of Rheumatoid Synovial Fibroblasts

U. Müller-Ladner, I. Tarner, S. Rehart, 2017, The Journal of Immunology.

Migratory potential of rheumatoid arthritis synovial fibroblasts: Additional perspectives

U. Müller-Ladner, S. Rehart, E. Neumann, 2010, Cell cycle.

The Pathogenesis of Systemic Sclerosis Revisited

U. Müller-Ladner, M. Geyer, 2011, Clinical reviews in allergy & immunology.

Animal Models of Scleroderma: From Cellular and Molecular Mechanisms to Novel Antifibrotic Strategies

U. Müller-Ladner, M. Manetti, O. Distler, 2009 .

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD

M. Dougados, F. Breedveld, N. Wulffraat, 2019, RMD Open.

Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.

D. Furst, U. Müller-Ladner, L. Czirják, 2015, Rheumatology.

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial

M. Baron, D. Furst, Haiyin Chen-Harris, 2016, The Lancet.

Web appendix F

Sang Joon Lee, Michael Tee, Pedro Miranda, 2013 .

Bile acids mimic oxidative stress induced upregulation of thioredoxin reductase in colon cancer cell lines.

M. McClelland, U. Müller-Ladner, J. Schölmerich, 2002, Carcinogenesis.

Rationale of using different biological therapies in rheumatoid arthritis

U. Müller-Ladner, M. Geyer, 2010, Arthritis research & therapy.

Rationale of using diff erent biological therapies in rheumatoid arthritis

U. Müller-Ladner, M. Geyer, 2010 .

Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases.

U. Müller-Ladner, J. Schölmerich, C. Fiehn, 2002, Arthritis and rheumatism.

Leukoencephalopathy and chronic pancreatitis as concomitant manifestations of systemic lupus erythematosus related to anticardiolipin antibodies

U. Müller-Ladner, C. Bruns, J. Link, 2004, Rheumatology International.

rheumatism collaborative initiative rheumatology / European league against sclerosis : an American college of 2013 classification criteria for systemic

M. Mayes, P. Merkel, M. Baron, 2013 .

Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort.

F. Spertini, A. Gabrielli, D. Rimar, 2019, Rheumatology.

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

J. Ioannidis, M. Dougados, N. Wulffraat, 2010, Annals of the rheumatic diseases.

Identification of influencing variables on adiponectin serum levels in diabetes mellitus type 1 and type 2.

U. Müller-Ladner, J. Schölmerich, H. Herfarth, 2004, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Evidence of an anti-inflammatory toll-like receptor 9 (TLR 9) pathway in adipocytes.

U. Müller-Ladner, E. Neumann, P. Pfefferle, 2019, The Journal of endocrinology.

Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX.

A. Wunder, U. Müller-Ladner, C. Fiehn, 2004, Rheumatology.

Gout--current diagnosis and treatment.

S. Bornstein, M. Aringer, U. Müller-Ladner, 2009, Deutsches Arzteblatt international.

Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers

M. Conforti, U. Müller-Ladner, R. Gay, 2002, Arthritis research.

Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database

U. Müller-Ladner, L. Czirják, O. Kowal‐Bielecka, 2008, Annals of the rheumatic diseases.

Elevated MMP‐7 levels in patients with systemic sclerosis: correlation with pulmonary involvement

M. Hellmich, S. Rosenkranz, U. Müller-Ladner, 2011, Experimental dermatology.

Sensitivity and specificity of ultrasonography and low-field magnetic resonance imaging for diagnosing arthritis.

U. Müller-Ladner, I. Tarner, K. Albrecht, 2012, Clinical and experimental rheumatology.

Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells.

U. Müller-Ladner, R. Gay, S. Gay, 2006, Arthritis and rheumatism.

Three-dimensional computed tomography for visualization of carotid bypasses in Takayasu arteritis.

U. Müller-Ladner, J. Schölmerich, S. Feuerbach, 2001, Rheumatology.

Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study

U. Müller-Ladner, I. Tarner, U. Lange, 2013, Clinical Rheumatology.

Fatal outcome of constrictive pericarditis in rheumatoid arthritis

U. Müller-Ladner, J. Schölmerich, B. Salzberger, 2003, Rheumatology International.

The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement

W. Lehmacher, C. Seitz, M. Meurer, 2008, Rheumatology.

[Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality].

U. Müller-Ladner, G. Riemekasten, M. Becker, 2010, Zeitschrift fur Rheumatologie.

Representativeness of Systemic Sclerosis Patients in Interventional Randomized Trials: an analysis of the EUSTAR database.

A. Gabrielli, U. Müller-Ladner, M. Vonk, 2021, Rheumatology.

[Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS)].

M. Meurer, U. Müller-Ladner, E. Schulze-Lohoff, 2008, Zeitschrift fur Rheumatologie.

Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study

U. Müller-Ladner, E. Hachulla, P. Carreira, 2016, PloS one.

Serum Vaspin Levels Are Associated with the Development of Clinically Manifest Arthritis in Autoantibody-Positive Individuals

P. Tak, U. Müller-Ladner, D. Gerlag, 2015, PloS one.

Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.

U. Müller-Ladner, J. Teichmann, U. Lange, 2005, Rheumatology.

[Osteoporosis: prophylaxis, diagnostics and therapy according to the guidelines].

U. Müller-Ladner, J. Pfeilschifter, U. Lange, 2011, Der Internist.

Association between the ACE gene I/D polymorphism and osteoporosis in a Turkish population

U. Müller-Ladner, 2015 .

The -2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis.

C. Hellerbrand, M. Landthaler, U. Müller-Ladner, 2005, The Journal of investigative dermatology.

Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs.

U. Müller-Ladner, J. Schölmerich, R. Straub, 1997, British journal of rheumatology.

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study

U. Müller-Ladner, S. Visovatti, C. Denton, 2014, Arthritis Research & Therapy.

Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis

U. Müller-Ladner, J. Braun, S. Rehart, 2022, Cells.

Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study

U. Müller-Ladner, V. Tesar, P. Heinzel, 2011, Arthritis Research & Therapy.

Vasculitides of the gastrointestinal tract.

U. Müller-Ladner, U. Müller-Ladner, 2001, Best practice & research. Clinical gastroenterology.

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics

R. Fischer-Betz, Matthias Schneider, U. Müller-Ladner, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

R. Fischer-Betz, U. Ziemann, H. Wiendl, 2011, Arthritis research & therapy.

Connective tissue diseases and pregnancy.

U. Müller-Ladner, W. Hermann, P. Saar, 2006, Rheumatology.

Interactions between rheumatoid arthritis synovial fibroblast migration and endothelial cells

U. Schumacher, U. Müller-Ladner, T. Gehrke, 2018, Immunology and cell biology.

EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells

A. Gabrielli, U. Müller-Ladner, A. Tyndall, 2008, Annals of the rheumatic diseases.

Effect of hypertension on echocardiographic parameters in rheumatoid arthritis

U. Müller-Ladner, 2014 .

Different effects of adiponectin isoforms in human monocytic cells

U. Müller-Ladner, J. Schölmerich, C. Wrede, 2006, Journal of leukocyte biology.

Adiponectin represents an independent cardiovascular risk factor predicting serum HDL‐cholesterol levels in type 2 diabetes

U. Müller-Ladner, J. Schölmerich, H. Herfarth, 2003, FEBS letters.

Expression of adipokines in osteoarthritis osteophytes and their effect on osteoblasts.

U. Müller-Ladner, G. Schett, S. Rehart, 2017, Matrix biology : journal of the International Society for Matrix Biology.

Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?

U. Müller-Ladner, S. Gay, S. Rehart, 2012, Annals of the rheumatic diseases.

The Adipokine Omentin in Late-stage Rheumatoid Arthritis and Endstage Osteoarthritis

U. Müller-Ladner, E. Neumann, K. Frommer, 2017, The Journal of Rheumatology.

Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis.

U. Müller-Ladner, J. Vencovský, S. Gay, 2012, Cytokine.

Systemic versus local adipokine expression differs in a combined obesity and osteoarthritis mouse model

U. Müller-Ladner, G. Schett, E. Roeb, 2021, Scientific Reports.

Profiling adipocytokine secretion from creeping fat in Crohn's disease

G. Rogler, U. Müller-Ladner, J. Schölmerich, 2006, Inflammatory bowel diseases.

Rheumatoid arthritis: The multifaceted role of adiponectin in inflammatory joint disease

U. Müller-Ladner, E. Neumann, 2009, Nature Reviews Rheumatology.

Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

S. Horton, M. Gianfrancesco, J. Yazdany, 2022, The Lancet Rheumatology.

MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction?

U. Müller-Ladner, S. Gay, 2002, Annals of the rheumatic diseases.

Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.

M. Landthaler, U. Müller-Ladner, J. Schölmerich, 2001, Arthritis and rheumatism.

Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis

M. Landthaler, U. Müller-Ladner, J. Schölmerich, 1999, Rheumatology International.

Role of adipokines in systemic sclerosis pathogenesis.

U. Müller-Ladner, E. Neumann, K. Frommer, 2020, European journal of rheumatology.

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

A. Silman, R. Madhok, K. Chakravarty, 2018, Annals of the rheumatic diseases.

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.

U. Müller-Ladner, L. Czirják, C. Denton, 2015, Annals of the rheumatic diseases.

Endogenous regeneration after collagenase-induced knee joint damage in the adult newt Notophthalmus viridescens

T. Borchardt, U. Müller-Ladner, A. Wietelmann, 2010, Annals of the rheumatic diseases.

Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology.

U. Müller-Ladner, S. Grässel, G. Schett, 2009, Osteoarthritis and cartilage.

Progressive joint destruction in a human immunodeficiency virus-infected patient with rheumatoid arthritis.

J. Kriegsmann, U. Müller-Ladner, R. Gay, 1995, Arthritis and rheumatism.

MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis.

A. Bosserhoff, U. Müller-Ladner, J. Schölmerich, 1999, Rheumatology.

Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein‐1 that are not influenced by the –2518 A→G promoter polymorphism

U. Müller-Ladner, J. Schölmerich, H. Herfarth, 2005, Diabetes, obesity & metabolism.

Vitamin D receptor FokI, BsmI, and TaqI polymorphisms and susceptibility to rheumatoid arthritis

U. Müller-Ladner, 2016 .

Cartilage erosion in rheumatoid arthritis: studies in SCID mouse model

U. Müller-Ladner, T. Pap, K. Hummel, 2000 .

Evaluation of a special concept of physical therapy in spondyloarthritis: German multimodal rheumatologic complex treatment for spondyloarthritis

U. Müller-Ladner, I. Tarner, U. Lange, 2020, Clinical Rheumatology.

Adipokines in bone disease

U. Müller-Ladner, G. Schett, E. Neumann, 2016, Nature Reviews Rheumatology.

Low-field magnetic resonance imaging study on carpal arthritis in systemic sclerosis - low-grade erosive arthritis of carpal bones is an unexpected and frequent disease manifestation

U. Müller-Ladner, I. Tarner, R. Dinser, 2013, Arthritis Research & Therapy.

Reduction of in vitro invasion and in vivo cartilage degradation in a SCID mouse model by loss of function of the fibrinolytic system of rheumatoid arthritis synovial fibroblasts.

U. Müller-Ladner, E. Neumann, M. Benucci, 2011, Arthritis and rheumatism.

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 1: Classification, diagnosis, prevention, activity scores

R. Fischer-Betz, Matthias Schneider, U. Müller-Ladner, 2021, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Adipokines and Inflammation Alter the Interaction Between Rheumatoid Arthritis Synovial Fibroblasts and Endothelial Cells

U. Müller-Ladner, I. Tarner, S. Rehart, 2020, Frontiers in Immunology.

Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib

U. Müller-Ladner, S. Rehart, E. Neumann, 2019, Front. Immunol..

The activin-follistatin anti-inflammatory cycle is deregulated in synovial fibroblasts

U. Müller-Ladner, T. Pap, I. Tarner, 2019, Arthritis Research & Therapy.

articleCell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts

U. Müller-Ladner, J. Schölmerich, S. Gay, 2015 .

Arthritis in patients with systemic sclerosis.

U. Müller-Ladner, J. Pons-Kühnemann, T. Schmeiser, 2012, European journal of internal medicine.

Rheumatoid synovial fibroblasts differentiate into distinct subsets in the presence of cytokines and cartilage

U. Müller-Ladner, A. Yemm, A. Filer, 2016, Arthritis Research & Therapy.

The different stages of synovitis: acute vs chronic, early vs late and non-erosive vs erosive.

U. Müller-Ladner, R. Gay, S. Gay, 2005, Best practice & research. Clinical rheumatology.

Activation of synoviocytes

U. Müller-Ladner, R. Gay, S. Gay, 2000, Current opinion in rheumatology.

Impact of Thiopurine Methyltransferase Activity and 6‐Thioguanine Nucleotide Concentrations in Patients with Chronic Inflammatory Diseases

U. Müller-Ladner, J. Schölmerich, E. Schütz, 2006, Annals of the New York Academy of Sciences.

New lines in therapy of Raynaud’s phenomenon

U. Müller-Ladner, S. Lambova, 2009, Rheumatology International.

Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis.

J. Kriegsmann, U. Müller-Ladner, R. Gay, 1995, Arthritis and rheumatism.

[The effect of obesity on disease activity of inflammatory rheumatic diseases].

U. Müller-Ladner, E. Neumann, A. Schäffler, 2021, Zeitschrift fur Rheumatologie.

Clinical and laboratory profiles of 136 systemic sclerosis patients with and without echocardiographically detected pulmonary hypertension

U. Müller-Ladner, 2015 .

Mechanisms of vascular damage in systemic sclerosis

U. Müller-Ladner, S. Gay, O. Distler, 2009, Autoimmunity.

Clinical image: occult large vessel vasculitis diagnosed by PET imaging

U. Müller-Ladner, J. Schölmerich, R. Wiest, 2001, Rheumatology International.

Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease

U. Müller-Ladner, D. Huscher, S. Gay, 2011, Annals of the rheumatic diseases.

Low bone mineral density and vitamin d deficiency correlated with genetics and other bone markers in female Turkish immigrants in Germany

U. Müller-Ladner, P. Kann, H. Tinneberg, 2016, Clinical Rheumatology.

A one-day double-labelling technique for tissue specimens: Immunogold-silver staining forin situ hybridization combined with alkaline phosphatase-anti-alkaline phosphatase (APAAP) immunohistochemistry for antigens

J. Kriegsmann, U. Müller-Ladner, R. Gay, 1996, The Histochemical Journal.

Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma).

S. Barnum, M. Landthaler, U. Müller-Ladner, 2000, The Journal of rheumatology.

HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men.

D. Furst, U. Müller-Ladner, O. Distler, 2000, Arthritis and rheumatism.

Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal.

U. Müller-Ladner, F. Ingegnoli, M. Cutolo, 2018, Autoimmunity reviews.

The role of capillaroscopy in differentiation of primary and secondary Raynaud’s phenomenon in rheumatic diseases: a review of the literature and two case reports

U. Müller-Ladner, S. Lambova, 2009, Rheumatology International.

[Most important vaccinations in patients with rheumatological diseases and why].

U. Müller-Ladner, C. Kneitz, 2020, Zeitschrift fur Rheumatologie.

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

M. Dougados, F. Breedveld, N. Wulffraat, 2019, RMD Open.

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

J. D. de Vries-Bouwstra, R. Fischer-Betz, Matthias Schneider, 2021, Nature Reviews Rheumatology.

Role of nuclear factor κb in synovial inflammation

U. Müller-Ladner, R. Gay, S. Gay, 2002 .

Microangiopathy in Inflammatory Diseases—Strategies in Surgery of the Lower Extremity

U. Müller-Ladner, I. Tarner, C. Heiss, 2022, Life.

Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis

W. Robinson, E. Engleman, U. Müller-Ladner, 2009, Proceedings of the National Academy of Sciences.

Vaccination and Inflammatory Arthritis: Overview of Current Vaccines and Recommended Uses in Rheumatology

U. Müller-Ladner, C. Müller-Ladner, 2013, Current Rheumatology Reports.

German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

C. Baerwald, Matthias Schneider, U. Müller-Ladner, 2013, Rheumatology International.

Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups

V. Strand, U. Müller-Ladner, B. Le Goff, 2018, Arthritis Research & Therapy.

Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis.

U. Müller-Ladner, Sabrina Bauer, C. Buechler, 2012, Experimental and molecular pathology.

Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population

U. Müller-Ladner, C. Denton, E. Hachulla, 2015, Rheumatology.

Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)

M. Aringer, U. Müller-Ladner, G. Burmester, 2021, Rheumatology.

AB0270 Treatment response to rituximab in combination with leflunomide is influenced by anticcp status in active rheumatoid arthritis: results from a multicenter randomised placebo-controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-STUDY)

M. Aringer, U. Müller-Ladner, S. Wassenberg, 2018, Rheumatoid arthritis – prognosis, predictors and outcome.

Motivation for and Barriers to Participation in Clinical Trials From the Perspective of Patients With Rheumatic Diseases and Chronic Musculoskeletal Pain

U. Müller-Ladner, I. Tarner, S. Vogt, 2018, The Open Rheumatology Journal.

[Molecular imaging in rheumatoid arthritis].

J. Grimm, A. Wunder, U. Müller-Ladner, 2003, Zeitschrift für Rheumatologie (Print).

The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review

U. Müller-Ladner, P. Taylor, L. Gossec, 2021, Journal of clinical medicine.

Signaling and effector pathways.

U. Müller-Ladner, R. Gay, S. Gay, 1999, Current opinion in rheumatology.

Chemokines and chemokine receptors in the pathogenesis of systemic sclerosis

U. Müller-Ladner, R. Gay, S. Gay, 2002, Modern rheumatology.

P123 Extracellular matrix attenuated matrix-degrading effects of visfatin during adipogenic MSC differentiation

U. Müller-Ladner, S. Rehart, E. Neumann, 2019, Abstracts.

Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection.

R. Bohle, U. Müller-Ladner, A. Gaumann, 2007, Arthritis and rheumatism.

Genotyping of Synovial Fibroblasts

U. Müller-Ladner, E. Neumann, M. Judex, 2007 .

Genotyping of synovial fibroblasts: cDNA array in combination with RAP-PCR in arthritis.

U. Müller-Ladner, S. Gay, E. Neumann, 2007, Methods in molecular medicine.

Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts.

D. Alexander, U. Müller-Ladner, R. Gay, 2005, Arthritis and rheumatism.

Differential Adherence of Osteoarthritis and Rheumatoid Arthritis Synovial Fibroblasts to Cartilage and Bone Matrix Proteins and its Implication for Osteoarthritis Pathogenesis

D. Heinegård, U. Müller-Ladner, J. Schölmerich, 2004, Scandinavian journal of immunology.

Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis

U. Müller-Ladner, R. Gay, S. Gay, 2004, Annals of the rheumatic diseases.

Detection of mRNA by non-radioactive direct primed in situ reverse transcription

P. Petrow, J. Kriegsmann, U. Müller-Ladner, 2001, Histochemistry and Cell Biology.

“Inverse wrap”: an improved implantation technique for virus-transduced synovial fibroblasts in the SCID mouse model for rheumatoid arthritis

U. Müller-Ladner, J. Schölmerich, R. Gay, 2001, Modern rheumatology.

Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts.

P. Petrow, J. Kriegsmann, U. Müller-Ladner, 2000, Arthritis and rheumatism.

Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts.

D. Green, U. Müller-Ladner, G. Firestein, 1999, Arthritis and rheumatism.

Molecular biology of cartilage and bone destruction.

U. Müller-Ladner, R. Gay, S. Gay, 1998, Current opinion in rheumatology.

Vaccination in patients with chronic rheumatic or autoimmune diseases.

U. Müller-Ladner, T. Glück, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Novel aspects in the epidemiology, pathophysiology and treatment of connective tissue diseases. Introduction.

U. Müller-Ladner, O. Distler, 2006, Rheumatology.

[A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].

U. Müller-Ladner, S. Wassenberg, A. Schwarting, 2020, Zeitschrift fur Rheumatologie.

European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research

R. Landewé, B. Toth, U. Müller-Ladner, 2008, Annals of the rheumatic diseases.

Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis

U. Müller-Ladner, M. Worm, N. Hunzelmann, 2020, Arthritis care & research.

Gene transfer in rheumatoid arthritis: a novel therapeutic approach.

U. Müller-Ladner, R. Gay, S. Gay, 2000, Clinical and experimental rheumatology.

[Osteoimmunology: how inflammation influences bone metabolism].

U. Müller-Ladner, G. Schett, E. Neumann, 2013, Deutsche medizinische Wochenschrift.

Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis

Ami A. Shah, R. Steele, M. Mayes, 2014, Clinical Rheumatology.

Tolerability and Patient/Physician Satisfaction with Subcutaneously Administered Methotrexate Provided in Two Formulations of Different Drug Concentrations in Patients with Rheumatoid Arthritis

U. Müller-Ladner, U. Pichlmeier, J. Braun, 2010, The open rheumatology journal.

Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads to Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis

Till Acker, Oliver Distler, Ulf Müller-Ladner, 2004, Circulation research.

Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis

U. Müller-Ladner, D. Huscher, G. Schett, 2017, Annals of the rheumatic diseases.

Cysteine proteinases in arthritis and inflammation

U. Müller-Ladner, 1996 .

Synovial mesenchymal reaction as a perpetuating principle.

J. Kriegsmann, U. Müller-Ladner, R. Gay, 1995, Scandinavian journal of rheumatology. Supplement.

Emerging targets of biologic therapies for rheumatoid arthritis

U. Müller-Ladner, S. Gay, I. Tarner, 2007, Nature Clinical Practice Rheumatology.

Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis

U. Müller-Ladner, K. Pavelka, S. Gay, 2009, Annals of the rheumatic diseases.

Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis

U. Müller-Ladner, L. Czirják, C. Denton, 2013, Annals of the rheumatic diseases.

Clinically relevant advances in rheumatoid arthritis therapy

U. Müller-Ladner, I. Tarner, E. Neumann, 2009, F1000 Medicine Reports.

Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID)

R. Fischer-Betz, M. Haubitz, M. Aringer, 2012, The Journal of Rheumatology.

Spontaneous pneumothorax in a patient with systemic sclerosis

U. Müller-Ladner, B. Lang, M. Zeuner, 1996, Clinical Rheumatology.

Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway

P. Robbins, U. Müller-Ladner, J. Schölmerich, 2002, Gene Therapy.

Correction

U. Müller-Ladner, K. Pavelka, S. Gay, 2009, Annals of the Rheumatic Diseases.

No evidence for a genetic association of IRF4 with systemic lupus erythematosus in a Chinese population

U. Müller-Ladner, 2014 .

The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

U. Müller-Ladner, L. Czirják, C. Denton, 2009, Annals of the rheumatic diseases.

Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis.

L. Messerini, U. Müller-Ladner, E. Roeb, 2008, Arthritis and rheumatism.

Current therapy of systemic sclerosis (scleroderma)

U. Müller-Ladner, B. Lang, K. Benning, 1993, The clinical investigator.

Review Developments in the synovial biology field 2006

U. Müller-Ladner, E. Neumann, A. Knedla, 2007 .

The burden of systemic sclerosis in Switzerland - the Swiss systemic sclerosis EUSTAR cohort.

A. Gabrielli, U. Müller-Ladner, P. Carreira, 2021, Swiss medical weekly.

Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database

F. Mendoza, J. D. de Vries-Bouwstra, M. Cerinic, 2020, Arthritis Research & Therapy.

Innovative Approaches to Clinical Trials in Systemic Sclerosis

U. Müller-Ladner, O. Distler, R. Dobrota, 2017 .

Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database

U. Müller-Ladner, E. Hachulla, P. Carreira, 2015, Annals of the rheumatic diseases.

Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database.

U. Müller-Ladner, L. Czirják, C. Denton, 2012, Rheumatology.

Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

M. Meurer, U. Müller-Ladner, F. Reichenberger, 2011, Arthritis research & therapy.

Gastrointestinal manifestation of systemic sclerosis--thickening of the upper gastrointestinal wall detected by endoscopic ultrasound is a valid sign.

U. Müller-Ladner, M. Fleck, F. Kullmann, 2010, Rheumatology.

High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy

W. Lehmacher, M. Meurer, U. Müller-Ladner, 2009, Arthritis research & therapy.

Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.

W. Lehmacher, M. Meurer, U. Müller-Ladner, 2008, Rheumatology.

Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients.

P. Bechi, U. Müller-Ladner, M. Manetti, 2007, Arthritis and rheumatism.

Insufficient Skin Angiogenesis in Patients With Systemic Sclerosis Uncontrolled Expression of Vascular Endothelial Growth Factor and Its Receptors Leads

T. Acker, U. Müller-Ladner, R. Gay, 2004 .

Doppler ultrasound identifies increased resistive indices in SSc

U. Müller-Ladner, J. Schölmerich, O. Distler, 2003, Annals of the Rheumatic Diseases.

[Therapy for secondary arthropathies: from psoriasis and Reiter's disease to hemochromatosis].

U. Müller-Ladner, A. Gödde, 2006, Der Internist.

Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis

U. Müller-Ladner, C. Fiehn, F. Kratz, 2008, Annals of the rheumatic diseases.

ArthritisTherapeutic Approach for Rheumatoid Albumin-Based Drug Delivery as Novel

A. Wunder, U. Müller-Ladner, S. Gay, 2003 .

Thioredoxin Reductase 1 Expression in Colon Cancer: Discrepancy between In Vitro and In Vivo Findings

U. Müller-Ladner, J. Schölmerich, J. Rüschoff, 2002, Laboratory Investigation.

Kinesin-like protein CENP-E is upregulated in rheumatoid synovial fibroblasts

U. Müller-Ladner, J. Schölmerich, S. Gay, 1999, Arthritis research.

Are fibroblasts involved in joint destruction?

U. Müller-Ladner, S. Gay, T. Pap, 2005, Annals of the rheumatic diseases.

[Analysis of gene expression patterns in rheumatoid synovial fibroblasts using RAP-PCR for differential display].

U. Müller-Ladner, J. Schölmerich, S. Gay, 1999, Medizinische Klinik.

T cell-independent joint destruction

U. Müller-Ladner, G. Burmester, T. Pap, 1998 .

Vasculitis of the aortic arch and cardiac valves as the cause of relapsing fever of unknown origin in an elderly, white man

U. Müller-Ladner, J. Schölmerich, F. Obermeier, 2006, Clinical Rheumatology.

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

J. D. de Vries-Bouwstra, R. Fischer-Betz, Matthias Schneider, 2021, Nature Reviews Rheumatology.

p53 in rheumatoid arthritis: friend or foe?

U. Müller-Ladner, K. Nishioka, 2000, Arthritis research.

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

U. Müller-Ladner, L. Czirják, C. Denton, 2007, Annals of the rheumatic diseases.

Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort.

M. Boubaya, F. Mendoza, J. D. de Vries-Bouwstra, 2022, The Lancet. Rheumatology.

Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort.

A. Gabrielli, U. Müller-Ladner, L. Rudnicka, 2021, Rheumatology.

The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients

A. Gabrielli, U. Müller-Ladner, M. Matucci-Cerinic, 2020, Expert review of clinical immunology.

Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study

U. Müller-Ladner, L. Czirják, C. Denton, 2019, Clinical Rheumatology.

Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey

U. Müller-Ladner, L. Czirják, C. Denton, 2019, Arthritis Research & Therapy.

Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved?

U. Müller-Ladner, L. Czirják, C. Denton, 2013, Annals of the rheumatic diseases.

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

U. Müller-Ladner, M. Matucci-Cerinic, G. Riemekasten, 2012, Annals of the rheumatic diseases.

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database

U. Müller-Ladner, L. Czirják, C. Denton, 2012, Annals of the rheumatic diseases.

Collagen Vascular and Vasculitic Disorders

U. Müller-Ladner, J. Schölmerich, 2012 .

Profile of gastrointestinal involvement in patients with systemic sclerosis

U. Müller-Ladner, R. Bretzel, E. Roeb, 2012, Rheumatology International.

Connective tissue diseases: Treatment of digital ulcers in systemic sclerosis

U. Müller-Ladner, S. Lambova, 2011, Nature Reviews Rheumatology.

Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors

J. Gerss, M. Meurer, U. Müller-Ladner, 2009, The British journal of dermatology.

["Pulmonary hypertension" of the gastrointestinal tract in patients with systemic sclerosis: thoughts on a not (yet) existing disease entity].

U. Müller-Ladner, U. Müller-Ladner, 2008, Deutsche medizinische Wochenschrift.

[Gastrointestinal involvement in systemic sclerosis. An underestimated complication].

U. Müller-Ladner, I. Tarner, P. Saar, 2007, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

Analysis of gene expression patterns in systemic sclerosis fibroblasts using RNA arbitrarily primed-polymerase chain reaction for differential display.

M. Landthaler, U. Müller-Ladner, S. Gay, 2007, The Journal of rheumatology.

Osteometabolic and osteogenetic pattern of Turkish immigrants in Germany.

L. Hofbauer, U. Müller-Ladner, I. Tarner, 2012, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

A Patient with Diffuse Systemic Sclerosis with Hypertension and Acute Renal Failure

U. Müller-Ladner, 2011 .

Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database

U. Müller-Ladner, O. Distler, C. Foocharoen, 2012, Scandinavian journal of rheumatology.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort

U. Müller-Ladner, C. Denton, D. Khanna, 2017, Annals of the Rheumatic Diseases.

Comparative transcriptional profiling of regenerating damaged knee joints in two animal models of the newt Notophthalmus viridescens strengthens the role of candidate genes involved in osteoarthritis

T. Borchardt, U. Müller-Ladner, M. Looso, 2022, Osteoarthritis and cartilage open.

Three dimensional power Doppler ultrasonography confirms early reduction of synovial perfusion after intra-articular steroid injection

U. Müller-Ladner, U. Lange, J. Strunk, 2006, Annals of the Rheumatic Diseases.

Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis.

A. Iagnocco, U. Müller-Ladner, A. Herrick, 2020, Autoimmunity reviews.

Safety and effi cacy of subcutaneous tocilizumab in adults with systemic sclerosis ( faSScinate ) : a phase 2 , randomised , controlled trial

M. Baron, D. Furst, Haiyin Chen-Harris, 2016 .

Anti-Jo-1 antibody positive polymyositis—successful therapy with leflunomide

U. Müller-Ladner, U. Lange, J. Strunk, 2006, Autoimmunity.

Laser-mediated microdissection facilitates analysis of area-specific gene expression in rheumatoid synovium.

U. Müller-Ladner, J. Schölmerich, S. Gay, 2003, Arthritis and rheumatism.

Toll-like Receptor 7 (TLR7) Is Expressed in Adipocytes and the Pharmacological TLR7 Agonist Imiquimod and Adipocyte-Derived Cell-Free Nucleic Acids (cfDNA) Regulate Adipocyte Function

U. Müller-Ladner, E. Neumann, A. Schäffler, 2022, International journal of molecular sciences.

Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry

U. Müller-Ladner, M. Worm, Hanns-Martin Lorenz, 2022, Arthritis Research & Therapy.

Differentiation of osteophyte types in osteoarthritis - proposal of a histological classification.

U. Müller-Ladner, G. Schett, S. Rehart, 2016, Joint, bone, spine : revue du rhumatisme.

A one‐year survey on the use of a powder from Rosa canina lito in acute exacerbations of chronic pain

U. Müller-Ladner, S. Chrubasik, A. Black, 2008, Phytotherapy research : PTR.

FRI0491 Incidence and Predictors of Cutaneous Manifestations During the Early Course of Systemic Sclerosis – A 10 Year Longitudinal Study from the Eustar Database

U. Müller-Ladner, E. Hachulla, P. Carreira, 2015 .

Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction.

P. Petrow, U. Müller-Ladner, R. Gay, 1998, The Journal of rheumatology.

Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.

U. Müller-Ladner, H. Hsu, J. Mountz, 2001, Arthritis and rheumatism.

RAP-PCR fingerprinting reveals time-dependent expression of matrix-related molecules following stem-cell based TGFβ1-induced chondrocyte development.

U. Müller-Ladner, J. Schölmerich, P. Angele, 2011, International journal of molecular medicine.

Ambulante Physiotherapie bei Osteoporose

U. Müller-Ladner, J. Teichmann, U. Lange, 2012, Zeitschrift für Rheumatologie.

Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective.

P. Robbins, U. Müller-Ladner, R. Gay, 1997, Journal of immunology.

Transcription Factor Egr-1 Activates Collagen Expression in Immortalized Fibroblasts or Fibrosarcoma Cells

D. Alexander, U. Müller-Ladner, S. Gay, 2002, Biological chemistry.

Achenbach's Syndrome (Paroxysmal Finger Hematoma) With Capillaroscopic Evidence of Microhemorrhages

U. Müller-Ladner, W. Hermann, M. Frerix, 2015, Arthritis & rheumatology.

Comment on: The Portuguese Society of Rheumatology position paper on the use of biosimilars.

U. Müller-Ladner, 2014, Acta reumatologica portuguesa.

German 2012 recommendations for the medical treatment of rheumatoid arthritis

U. Müller-Ladner, 2013 .

The new 2012 German recommendations for treating rheumatoid arthritis

U. Müller-Ladner, K. Krüger, J. Wollenhaupt, 2013, Zeitschrift für Rheumatologie.

Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis.

R. Wenger, U. Müller-Ladner, R. Gay, 2009, Arthritis and rheumatism.

Tenosynovial nodulosis in a patient infected with human T cell lymphotropic virus I.

U. Müller-Ladner, S. Gay, K. Nishioka, 1997, Arthritis and rheumatism.

Visfatin alters the cytokine and matrix-degrading enzyme profile during osteogenic and adipogenic MSC differentiation.

D. Hose, U. Müller-Ladner, S. Rehart, 2018, Osteoarthritis and cartilage.

Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)

M. Aringer, U. Müller-Ladner, S. Wassenberg, 2022, Journal of clinical medicine.

FRI0143 A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis

U. Müller-Ladner, P. Miranda, W. Park, 2013 .

[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].

U. Müller-Ladner, U. Lange, N. Steinchen, 2020, Zeitschrift fur Rheumatologie.

Response of human rheumatoid arthritis osteoblasts and osteoclasts to adiponectin.

U. Müller-Ladner, G. Schett, S. Rehart, 2017, Clinical and experimental rheumatology.

[Modern disease-modifying antirheumatic drugs].

U. Müller-Ladner, I. Tarner, K. Richter, 2015, Der Internist.

Targeted gene therapy: frontiers in the development of 'smart drugs'.

U. Müller-Ladner, I. Tarner, C. Fathman, 2004, Trends in biotechnology.

Faculty Opinions recommendation of Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.

U. Müller-Ladner, 2010 .

Clinical images: Skin necrosis in giant cell arteritis.

U. Müller-Ladner, O. Distler, T. Glück, 1999, Arthritis and rheumatism.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Tsutomu Takeuchi, René Westhovens, Désirée van der Heijde, 2020, Annals of the Rheumatic Diseases.

Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group

A. Gabrielli, U. Müller-Ladner, D. Huscher, 2018, Rheumatology.

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study

A. Silman, R. Madhok, K. Chakravarty, 2017, Rheumatology.

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.

S. Jimenez, U. Müller-Ladner, L. Czirják, 2020, Rheumatology.

Inhomogeneity of capillaroscopic findings in systemic sclerosis

U. Müller-Ladner, S. Lambova, 2019, International journal of rheumatic diseases.

Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung

A. Prasse, U. Müller-Ladner, F. Bonella, 2019, Zeitschrift für Rheumatologie.

SAT0296 FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN

U. Müller-Ladner, A. Herrick, C. Denton, 2019, Autoimmunity reviews.

Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

U. Müller-Ladner, L. Czirják, C. Denton, 2018, Arthritis & rheumatology.

Mosaic capillaroscopic findings in systemic sclerosis

U. Müller-Ladner, S. Lambova, 2018, Wiener Medizinische Wochenschrift.

There is a need for new systemic sclerosis subset criteria. A content analytic approach

Shervin, M. Baron, A. Gabrielli, 2018, Scandinavian journal of rheumatology.

Mapping and predicting mortality from systemic sclerosis

M. Boubaya, A. Gabrielli, U. Müller-Ladner, 2017, Annals of the rheumatic diseases.

The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index

M. Baron, U. Müller-Ladner, L. Czirják, 2016, Annals of the rheumatic diseases.

Update of EULAR recommendations for the treatment of systemic sclerosis

D. Furst, U. Müller-Ladner, L. Czirják, 2015, Annals of the rheumatic diseases.

Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study

F. Spertini, W. Grassi, U. Müller-Ladner, 2016, Arthritis & rheumatology.

Is osteonecrosis of the lunate bone an underestimated feature of systemic sclerosis? A case series of nine patients and review of literature.

U. Müller-Ladner, I. Tarner, G. Szalay, 2016, Seminars in arthritis and rheumatism.

An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

M. Mayes, P. Merkel, M. Baron, 2013 .

Novel molecular and epidemiological features of disease

U. Müller-Ladner, Akademisk Avhandling, K. Andréasson, 2013 .

An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database.

U. Müller-Ladner, A. Tyndall, P. Carreira, 2015, Clinical and experimental rheumatology.

A systematic review on the Rosa canina effect and efficacy profiles

U. Müller-Ladner, S. Chrubasik, B. Roufogalis, 2007, Phytotherapy research : PTR.

Potential molecular basis of the chondroprotective effect of Harpagophytum procumbens.

U. Müller-Ladner, S. Chrubasik, E. Neumann, 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.

A Pilot Study on the Effectiveness of a Rose Hip Shell Powder in Patients Suffering from Chronic Musculoskeletal Pain

U. Müller-Ladner, E. Neumann, S. Chrubasik-Hausmann, 2014, Phytotherapy research : PTR.

Therapeutic management of pyoderma gangrenosum.

F. Klebl, U. Müller-Ladner, S. Karrer, 2004, Arthritis and rheumatism.

Gut and Liver in Vasculitic Disorders

U. Müller-Ladner, 2016, Digestive Diseases.

["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept].

A. Heiligenhaus, U. Müller-Ladner, K. Reich, 2009, Deutsche medizinische Wochenschrift.

Einternational panel of rheumatologists in the research and expert opinion of a broad arthritis : integrating systematic literature undifferentiated peripheral inflammatory on how to investigate and follow-up Multinational evidence-based recommendations

C. Bombardier, R. Landewé, U. Müller-Ladner, 2010 .

Role of adipose tissue as an inflammatory organ in human diseases.

U. Müller-Ladner, J. Schölmerich, A. Schäffler, 2006, Endocrine reviews.

Long-term effects of chondrospheres on cartilage lesions in an autologous chondrocyte implantation model as investigated in the SCID mouse model.

J Grifka, U. Müller-Ladner, J. Schölmerich, 2009, International journal of molecular medicine.

Gene Transfer to Synovial Fibroblast

U. Müller-Ladner, T. Pap, I. Meinecke, 2007 .

Gene transfer to synovial fibroblast: methods and evaluation in the SCID mouse model.

U. Müller-Ladner, S. Gay, T. Pap, 2007, Methods in molecular medicine.

Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts

Oliver Distler, Thomas Pap, Ulf Müller-Ladner, 2007, Arthritis Research & Therapy.

Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners.

A. Bosserhoff, U. Müller-Ladner, R. Gay, 2000, Osteoarthritis and cartilage.

Mechanisms of Disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis

Thomas Pap, Ulf Müller-Ladner, U. Müller-Ladner, 2005, Nature Clinical Practice Rheumatology.

Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts.

U. Müller-Ladner, R. Gay, S. Gay, 1996, The Journal of rheumatology.

Current immunotherapy in rheumatoid arthritis.

U. Müller-Ladner, W. Hermann, F. Meier, 2013, Immunotherapy.

GEPARD-Patientenfragebogen

T. Vogt, U. Müller-Ladner, I. Tarner, 2010, Zeitschrift für Rheumatologie (Print).

[Detection of psoriasis arthritis with the GEPARD patient questionnaire in a dermatologic outpatient setting].

T. Vogt, U. Müller-Ladner, I. Tarner, 2010, Zeitschrift fur Rheumatologie.

The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis

U. Müller-Ladner, I. Tarner, U. Lange, 2009, Clinical Rheumatology.

The Adipokine Network in Rheumatic Joint Diseases

U. Müller-Ladner, R. Gomariz, E. Neumann, 2019, International journal of molecular sciences.

Erratum to “Rheumatoid arthritis progression mediated by activated synovial fibroblasts” [Trends in Molecular Medicine 16 (2010) 10]

U. Müller-Ladner, E. Neumann, S. Lefèvre, 2011 .

Evaluation of differentially expressed genes by a combination of cDNA array and RAP-PCR using the AtlasImage 2.0 software.

U. Müller-Ladner, J. Schölmerich, J. Rüschoff, 2003, Journal of autoimmunity.

Gene expression pattern of laser microdissected colonic crypts of adenomas with low grade dysplasia

U. Müller-Ladner, J. Schölmerich, J. Rüschoff, 2003, Gut.

Arthritis

Thomas Pap, Ulf Müller-Ladner, U. Müller-Ladner, 2000, Nature Biotechnology.

Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice.

J. Kriegsmann, U. Müller-Ladner, R. Gay, 1996, The American journal of pathology.

Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression

U. Müller-Ladner, U. Syrbe, E. Neumann, 2015, Arthritis & rheumatology.

p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion

U. Müller-Ladner, G. Firestein, R. Gay, 2003, Annals of the rheumatic diseases.

Commentary p53 in rheumatoid arthritis: friend or foe?

U. Müller-Ladner, K. Nishioka, 2000 .

Sequential Combination Therapy Leading to Sustained Remission in a Patient with SAPHO Syndrome

U. Müller-Ladner, J. Schölmerich, S. Feuerbach, 2009, The open rheumatology journal.

[Treatment of rheumatic diseases and pulmonary toxicity].

U. Müller-Ladner, J. Schreiber, 2018, Der Pneumologe.

Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts.

D. Alexander, U. Müller-Ladner, C. Mawrin, 2004, Arthritis and rheumatism.

Year : 2002 Ex vivo gene transfer in the years to come Pap

U. Müller-Ladner, R. Gay, S. Gay, 2007 .

Ex vivo gene transfer in the years to come

U. Müller-Ladner, R. Gay, S. Gay, 2001, Arthritis research.

Native albumin for targeted drug delivery

Eva Frei, Matthias D Becker, Elena Neumann, 2010, Expert opinion on drug delivery.

Gene targeting: Roadmap to future therapies

U. Müller-Ladner, R. Gay, S. Gay, 2004, Current rheumatology reports.

Gene transfer as a future therapy for rheumatoid arthritis

U. Müller-Ladner, R. Gay, S. Gay, 2003, Expert opinion on biological therapy.

Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.

T. Vogt, U. Müller-Ladner, J. Schölmerich, 2005, Rheumatology.

The Role of Corticosteroids for Pain Relief in Persistent Pain of Inflammatory Arthritis: A Systematic Literature Review

D. M. van der Heijde, Matthias Schneider, U. Müller-Ladner, 2012, The Journal of Rheumatology. Supplement.

Chemokine receptor 5 Δ32 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren's syndrome

U. Müller-Ladner, 2014 .

References Subscriptions Permissions Email Alerts Activation of the IL-4 STAT Pathway in

U. Müller-Ladner, J. Schölmerich, R. Gay, 2013 .

Rheumatoid Synovium Activation of the IL-4 STAT Pathway in

U. Müller-Ladner, J. Schölmerich, R. Gay, 2000 .

[Revised version of the statement by the DGRh on biosimilars-update 2017].

U. Müller-Ladner, T. Dörner, H. Schulze-Koops, 2018, Zeitschrift fur Rheumatologie.

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis

P. Emery, U. Müller-Ladner, P. Mease, 2011, Rheumatology.

Faculty Opinions recommendation of Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma.

U. Müller-Ladner, E. Neumann, 2014 .

Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative

C. Bombardier, C. van Durme, R. Buchbinder, 2013, Annals of the rheumatic diseases.

Mixed connective tissue disease: state of the art on clinical practice guidelines

R. Fischer-Betz, Matthias Schneider, U. Müller-Ladner, 2018, RMD Open.

Identification of differentially expressed genes in rheumatoid arthritis by a combination of complementary DNA array and RNA arbitrarily primed-polymerase chain reaction.

U. Müller-Ladner, J. Schölmerich, S. Gay, 2002, Arthritis and rheumatism.

Use of Simplified Transcriptors for the Analysis of Gene Expression Profiles in Laser-Microdissected Cell Populations

U. Müller-Ladner, J. Schölmerich, J. Rüschoff, 2001, Laboratory Investigation.

[Gout as a systemic disease. Manifestations, complications and comorbidities of hyperuricaemia].

U. Müller-Ladner, A. Tausche, B. Manger, 2012, Zeitschrift fur Rheumatologie.

Registries in systemic sclerosis: a worldwide experience.

M. Baron, U. Müller-Ladner, C. Denton, 2011, Rheumatology.

Delivery of antisense constructs and ribozymes to inhibit cartilage destruction in the SCID mouse model of RA

U. Müller-Ladner, R. Gay, S. Gay, 2001, Arthritis Research.

Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis.

U. Müller-Ladner, R. Gay, S. Gay, 2000, Arthritis and rheumatism.

Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model.

P. Robbins, U. Müller-Ladner, R. Gay, 1999, Arthritis and rheumatism.

Cellular pathways of joint destruction.

U. Müller-Ladner, R. Gay, S. Gay, 1997, Current opinion in rheumatology.

Molecular and cellular interactions in rheumatoid synovium.

U. Müller-Ladner, 1996, Current opinion in rheumatology.

Methotrexate-Induced Accumulation of Fluorescent Annexin V in Collagen-Induced Arthritis

R. Weissleder, L. Josephson, E. Schellenberger, 2005, Molecular imaging.

Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo

A. Wunder, U. Müller-Ladner, C. Fiehn, 2004, Annals of the rheumatic diseases.

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience

Uwe Pichlmeier, Ulf Müller-Ladner, U. Müller-Ladner, 2014, Patient preference and adherence.

Comparison of patient satisfaction with two different etanercept delivery systems

U. Müller-Ladner, R. Flipo, Y. Brault, 2012, Zeitschrift für Rheumatologie.

Quantification of the synovial perfusion in rheumatoid arthritis using Doppler ultrasonography.

U. Müller-Ladner, U Müller-Ladner, K. Albrecht, 2007, Clinical and experimental rheumatology.

Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach.

U. Müller-Ladner, J. Schölmerich, R. Straub, 2005, Rheumatology.

[Serial whole-body cryotherapy in the criostream for inflammatory rheumatic diseases. A pilot study].

U. Müller-Ladner, U. Lange, C. Uhlemann, 2008, Medizinische Klinik.

Serial whole-body cryotherapy in fibromyalgia is effective and alters cytokine profiles

U. Müller-Ladner, E. Neumann, U. Lange, 2021, Advances in Rheumatology.

Efficacy of Intensive Physiotherapy in Combination with Low-dose Etanercept in Active Spondyloarthritis: A Monocentric Pilot Study

U. Müller-Ladner, U. Lange, F. Meier, 2014, The Journal of Rheumatology.

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

M. Dougados, N. Wulffraat, R. Landewé, 2019, Annals of the rheumatic diseases.

Rheumatic Diseases and Molecular Physical Medicine – New Aspects

U. Müller-Ladner, U. Lange, G. Dischereit, 2017, Physikalische medizin, rehabilitationsmedizin, kurortmedizin.

Different effects of local cryogel and cold air physical therapy in wrist rheumatoid arthritis visualised by power Doppler ultrasound

U. Müller-Ladner, K. Albrecht, U. Lange, 2009, Annals of the rheumatic diseases.

Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis

U. Müller-Ladner, J. Teichmann, U. Lange, 2005, Osteoporosis International.

Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab.

T. Vogt, U. Müller-Ladner, S. Karrer, 2005, Arthritis and rheumatism.

The impact of serial radon and hyperthermia exposure in a therapeutic adit on pivotal cytokines of bone metabolism in rheumatoid arthritis and osteoarthritis

U. Müller-Ladner, I. Tarner, E. Neumann, 2016, Clinical Rheumatology.

[Physiotherapeutic and rehabilitation therapy for ankylosing spondylitis. Status quo and are they still necessary in the age of anti-cytokine therapy?].

U. Müller-Ladner, U. Lange, C. Uhlemann, 2007, Zeitschrift fur Rheumatologie.

Multimodal rheumatologic complex treatment in patients with spondyloarthritis - a prospective study.

U. Müller-Ladner, I. Tarner, E. Neumann, 2021, European journal of internal medicine.

Effects of Osteoporosis Specific Standardized Physical Therapy on Functional Capacity, Bone Mineral Density and Bone Metabolism – a 2-Year Prospective and Randomized Study

U. Müller-Ladner, U. Lange, G. Dischereit, 2016, Physikalische Medizin, Rehabilitationsmedizin, Kurortmedizin.

Balneotherapy in rheumatic diseases–an overview of novel and known aspects

U. Müller-Ladner, U. Lange, K. Schmidt, 2006, Rheumatology International.

Interobserver Agreement in Two- and Three-Dimensional Power Doppler Sonographic Assessment of Synovial Vascularity during Anti-Inflammatory Treatment in Patients with Rheumatoid Arthritis

U. Müller-Ladner, U. Lange, J. Strunk, 2007, Ultraschall in der Medizin.

Two- and three-dimensional Doppler sonographic evaluation of the effect of local cryotherapy on synovial perfusion in wrist arthritis.

U. Müller-Ladner, U. Lange, J. Strunk, 2006, Rheumatology.

Functional genomics of fibroblasts

U. Müller-Ladner, R. Gay, S. Gay, 2004, Current opinion in rheumatology.

In Vitro Superfusion Method to Study Nerve‐Immune Cell Interactions in Human Synovial Membrane in Long‐standing Rheumatoid Arthritis or Osteoarthritis a

U. Müller-Ladner, J. Schölmerich, W. Falk, 1999, Annals of the New York Academy of Sciences.

Free Fatty Acids in Bone Pathophysiology of Rheumatic Diseases

C. Culmsee, U. Müller-Ladner, M. Zaiss, 2019, Front. Immunol..

Microsatellite analysis in rheumatoid arthritis synovial fibroblasts

U. Müller-Ladner, J. Schölmerich, J. Rüschoff, 2000, Annals of the rheumatic diseases.

Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?

U. Müller-Ladner, E. Neumann, K. Frommer, 2011, Arthritis and rheumatism.

Oxford Textbook of Rheumatology

J. Isaacs, U. Müller-Ladner, C. Denton, 2013 .

A case of recurrent abdominal bleeding due to polyarteritis nodosa despite immunosuppressive therapy

U. Müller-Ladner, S. Siebig, C. Wrede, 2007, Scandinavian journal of rheumatology.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

M. Baron, D. Furst, U. Müller-Ladner, 2017, Annals of the rheumatic diseases.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Edgar Ramiterre, Nenad Prodanovic, Mauricio Abello-Banfi, 2013, Annals of the rheumatic diseases.

The specificity of capillaroscopic pattern in connective autoimmune diseases. A comparison with microvascular changes in diseases of social importance: arterial hypertension and diabetes mellitus

Ulf Müller-Ladner, U. Müller-Ladner, S. Lambova, 2009, Modern rheumatology.

Capillaroscopic Pattern at the Toes of Systemic Sclerosis Patients: Does It "Tell" More Than Those of Fingers?

U. Müller-Ladner, S. Lambova, W. Hermann, 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

Capillaroscopic features of microangiopathy in rheumatoid arthritis patients with peripheral vascular syndrome

U. Müller-Ladner, S. Lambova, 2019, Clinical Rheumatology.

Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases.

Oliver Distler, Maurizio Cutolo, Amelia C Trombetta, 2018, Rheumatology.

An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases.

Oliver Distler, Maurizio Cutolo, Alberto Sulli, 2016, Rheumatology.

Genomic organization, chromosomal localization and adipocytic expression of the murine gene for CORS-26 (collagenous repeat-containing sequence of 26 kDa protein).

U. Müller-Ladner, J. Schölmerich, H. Herfarth, 2003, Biochimica et biophysica acta.

Digital Ulcers in Systemic Sclerosis - Frequency, Subtype Distribution and Clinical Outcome.

U. Müller-Ladner, S. Lambova, A. Batalov, 2013, Current rheumatology reviews.

Capillaroscopic findings in systemic sclerosis -- are they associated with disease duration and presence of digital ulcers?

U. Müller-Ladner, S. Lambova, 2011, Discovery medicine.

Capillaroscopic pattern in systemic sclerosis - an association with dynamics of processes of angio- and vasculogenesis.

U. Müller-Ladner, S. Lambova, 2010, Microvascular research.

Therapeutische Strategien im Frühstadium der systemischen Sklerose

U. Müller-Ladner, W. Hermann, M. Frerix, 2013, Zeitschrift für Rheumatologie (Print).

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)

A. Silman, R. Madhok, K. Chakravarty, 2017, Annals of the rheumatic diseases.

Skin involvement in systemic sclerosis.

U. Müller-Ladner, L. Czirják, I. Foeldvari, 2008, Rheumatology.

Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis

U. Müller-Ladner, R. Gay, S. Gay, 2004, Gene Therapy.

[Chronic anaemia in a patient with hereditary haemorrhagic telangiectasia and juvenile gastric polyposis].

U. Müller-Ladner, J. Schölmerich, S. Blaas, 2006, Deutsche Medizinische Wochenschrift.

[Chronic recurrent polychondritis].

U. Müller-Ladner, B. Lang, G. Rauh, 1993, Zeitschrift für Rheumatologie (Print).

The Elicitation of Rheumatic Symptoms at Vascular Sites

U. Müller-Ladner, M. Geyer, 2015 .

Enhanced expression of chemotactic receptors in multiple sclerosis lesions

S. Barnum, U. Müller-Ladner, S. Gay, 1996, Journal of the Neurological Sciences.

Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases.

J. Ioannidis, M. Dougados, C. Kallenberg, 2011, Autoimmunity reviews.

HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc

M. Gassmann, U. Müller-Ladner, R. Gay, 2002, Arthritis Research.

The miR-146a polymorphism and susceptibility to systemic lupus erythematosus and rheumatoid arthritis

U. Müller-Ladner, 2015 .

The association between susceptibility to inflammatory arthritis and miR-146a, miR-499 and IRAK1 polymorphisms

U. Müller-Ladner, 2015 .

Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis1

A. Wunder, U. Müller-Ladner, S. Gay, 2003, The Journal of Immunology.

Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum

U. Müller-Ladner, K. Pavelka, L. Šenolt, 2006, Annals of the rheumatic diseases.

Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives

W. Lieb, U. Müller-Ladner, B. Hoyer, 2021, Frontiers in Immunology.

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

L. Trupin, M. Gianfrancesco, J. Yazdany, 2021, Annals of the Rheumatic Diseases.

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis

F. Spertini, D. Furst, P. Emery, 2019, Arthritis & rheumatology.

SAT0204 The Eular Systemic Sclerosis Impact of Disease (ScleroID) Score – A New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis under Development

U. Müller-Ladner, M. Matucci-Cerinic, O. Distler, 2016 .

Patient Satisfaction with the Etanercept Biosimilar SB4 Device, Among Rheumatoid Arthritis and Spondyloarthropathy Patients - A German Observational Study

U. Müller-Ladner, C. Maucksch, P. Aries, 2020 .

[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].

U. Müller-Ladner, A. Schwarting, H. Schulze-Koops, 2016, Zeitschrift fur Rheumatologie.

Measuring Pain and Efficacy of Pain Treatment in Inflammatory Arthritis: A Systematic Literature Review

C. Bombardier, D. M. van der Heijde, U. Müller-Ladner, 2012, The Journal of Rheumatology. Supplement.

Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!

U. Müller-Ladner, C. Hamm, I. Tarner, 2010, F1000 medicine reports.

in the 3E Initiative of a broad international panel of rheumatologists systematic literature research and expert opinion with a focus on rheumatoid arthritis: integrating disorders for the use of methotrexate in rheumatic Multinational evidence-based recommendations

U. Müller-Ladner, L. Carmona, J. Bijlsma, 2009 .

A Plant-Derived Ligand Favoring Monomeric Glucocorticoid Receptor Conformation with Impaired Transactivation Potential Attenuates Collagen-Induced Arthritis1

S. van Calenbergh, G. Haegeman, D. Deforce, 2008, The Journal of Immunology.

Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways.

U. Müller-Ladner, R. Gay, S. Gay, 2004, Molecular pharmacology.

G protein-coupled receptors in rheumatology

U. Müller-Ladner, E. Neumann, K. Khawaja, 2014, Nature Reviews Rheumatology.

[Rheumatoid arthritis: new developments in the pathogenesis with special reference to synovial fibroblasts].

U. Müller-Ladner, R. Gay, S. Gay, 2001, Zeitschrift fur Rheumatologie.

Local production of complement proteins in rheumatoid arthritis synovium.

S. Barnum, U. Müller-Ladner, J. Schölmerich, 2002, Arthritis and rheumatism.

Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis.

U. Müller-Ladner, J. Teichmann, U. Lange, 2007, European Journal of Medical Research.

FRI0217 Impact of rituximab in combination with leflunomide and rituximab retreatment with two different dosages on patient-reported outcomes: results from a multicenter randomized placebo controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-STUDY)

M. Aringer, U. Müller-Ladner, G. Burmester, 2017 .

[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].

Andreas Krause, C. Baerwald, U. Müller-Ladner, 2012, Zeitschrift fur Rheumatologie.

Psychological effects of calisthenic exercises on neuroinflammatory and rheumatic diseases

U. Müller-Ladner, 2015 .

[Fatal sinus vein thrombosis in a patient with mixed connective tissue disease and secondary antiphospholipid antibody syndrome].

U. Müller-Ladner, J. Schölmerich, T. Glück, 2001, Medizinische Klinik.

[Bronchobiliary fistula associated with combined abscess of lung and liver].

U. Müller-Ladner, J. Schölmerich, F. Kullmann, 2004, Medizinische Klinik.

Rheumatoid and Degenerative Arthritis-Associated Inflammation

U. Müller-Ladner, M. Geyer, 2016 .

[Rheumatology - Integration into student training (RISA) : Current structure of clinical rheumatology in German universities (RISA III)].

C. Baerwald, M. Aringer, U. Müller-Ladner, 2016, Zeitschrift fur Rheumatologie.

[Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"].

K. Minden, R. Fischer-Betz, M. Aringer, 2016, Zeitschrift fur Rheumatologie.

The effects of a single carbon dioxide and hot water hand bath on acral perfusion in systemic sclerosis: A randomized, clinical study

U. Müller-Ladner, I. Tarner, Uwe Lange , 2019, Journal of scleroderma and related disorders.

Acute haemodynamic response to carbon dioxide hand immersion in patients with systemic sclerosis evaluated by Doppler ultrasonography.

U. Müller-Ladner, I. Tarner, M. Müller-Eschner, 2013, Clinical and experimental rheumatology.

Visfatin/Pre-B-cell Colony-enhancing Factor (PBEF), a Proinflammatory and Cell Motility-changing Factor in Rheumatoid Arthritis*

Elena Neumann, Ulf Müller-Ladner, U. Müller-Ladner, 2012, The Journal of Biological Chemistry.

Potential adipokine involvement in systemic sclerosis

A. Günther, U. Müller-Ladner, S. Gay, 2010 .

Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis.

U. Müller-Ladner, J. Zwerina, G. Schett, 2008, Arthritis and rheumatism.

Unifying abbreviations for biologics in rheumatology--does the idea hold promise?

U. Müller-Ladner, 2009, Rheumatology.

The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis

U. Müller-Ladner, J. Schölmerich, S. Gay, 2008, Annals of the rheumatic diseases.

Renal complications and scleroderma renal crisis.

U. Müller-Ladner, L. Mouthon, C. Denton, 2006, Rheumatology.

Drug delivery systems for the treatment of rheumatoid arthritis

U. Müller-Ladner, I. Tarner, 2008 .

Molekulare Pathologie der Arthrose

U. Müller-Ladner, R. Dinser, E. Neumann, 2008, Arthritis und Rheuma.

Influence of Extracellular RNAs, Released by Rheumatoid Arthritis Synovial Fibroblasts, on Their Adhesive and Invasive Properties

K. Preissner, U. Müller-Ladner, S. Rehart, 2016, The Journal of Immunology.

Dopamine induces in vitro migration of synovial fibroblast from patients with rheumatoid arthritis

U. Müller-Ladner, M. Cutolo, S. Rehart, 2020, Scientific Reports.

Expression of Brachyury in mesenchymal progenitor cells leads to cartilage‐like tissue that is resistant to the destructive effect of rheumatoid arthritis synovial fibroblasts

U. Müller-Ladner, G. Pelled, D. Gazit, 2009, Journal of tissue engineering and regenerative medicine.

Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients

U. Müller-Ladner, M. Richter, U. Lange, 2017, Clinical transplantation.

This information is current as on Their Adhesive and Invasive Properties Rheumatoid Arthritis Synovial Fibroblasts , Influence of Extracellular RNAs , Released by Preissner ,

U. Müller-Ladner, S. Rehart, E. Neumann, 2016 .

Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

S. Horton, M. Gianfrancesco, J. Yazdany, 2021, The Lancet Rheumatology.

Molecular imaging: novel tools in visualizing rheumatoid arthritis.

A. Wunder, U. Müller-Ladner, S. Gay, 2005, Rheumatology.

Points to consider in renal involvement in systemic sclerosis

D. Furst, U. Müller-Ladner, D. Khanna, 2017, Rheumatology.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis

M. Baron, D. Furst, U. Müller-Ladner, 2018, Rheumatology.

Linking systemic angiogenic factors (VEGF, angiogenin, TIMP-2) and Doppler ultrasound to anti-inflammatory treatment in rheumatoid arthritis.

U. Müller-Ladner, E. Neumann, K. Albrecht, 2013, Joint, bone, spine : revue du rhumatisme.

Standardized nailfold capillaroscopy in children with rheumatic diseases: a worldwide study

U. Müller-Ladner, A. Herrick, F. Ingegnoli, 2022, Rheumatology.

AB1088 Nailfold Capillaroscopy of the Toes in Healthy Subjects

U. Müller-Ladner, S. Lambova, 2015 .

Alternatively spliced CS-1 fibronectin isoform and its receptor VLA-4 in rheumatoid arthritis synovium.

J. Kriegsmann, U. Müller-Ladner, G. Firestein, 1997, The Journal of rheumatology.

[Rheumatoid arthritis. Systemic inflammation and cardiovascular morbidity].

U. Müller-Ladner, E. Decker, 2013, Der Internist.

The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.

J. D. de Vries-Bouwstra, R. Fischer-Betz, Matthias Schneider, 2022, Clinical and experimental rheumatology.

[A wolf in sheep's clothing: atypical systemic lupus erythematosus (SLE) presenting as cardiovascular disease].

U. Müller-Ladner, R. Kandolf, I. Tarner, 2010, Medizinische Klinik.

A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany

Andreas Krause, U. Müller-Ladner, H. Lorenz, 2021, Rheumatology International.

Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome.

U. Müller-Ladner, I. Tarner, U. Lange, 2020, Autoimmunity reviews.

Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammation.

C. Culmsee, K. Preissner, H. Bisgaard, 2016, The Journal of allergy and clinical immunology.

EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research

Oliver Distler, Maurizio Cutolo, Serena Guiducci, 2011, Annals of the rheumatic diseases.

[Is complete immunity against measles a realistic target for patients with rheumatic diseases and how can it possibly be achieved?]

U. Müller-Ladner, J. Braun, U. Kiltz, 2020, Zeitschrift für Rheumatologie (Print).

Osteoarthritis - Current Insights in Pathogenesis, Diagnosis and Treatment.

U. Müller-Ladner, S. Lambova, 2018, Current rheumatology reviews.

Nonerosive metacarpophalangeal arthritides in a patient with dermatomyositis.

U. Müller-Ladner, J. Schölmerich, M. Völk, 2004, The Journal of rheumatology.

OP0068 A Phase 3 Randomised Controlled Trial to Compare CT-P13 with Infliximab in Patients with Active Rheumatoid Arthritis: 54 Week Results from the Planetra Study

U. Müller-Ladner, S. Navarra, W. Park, 2013 .

OP0283 DOES TNF-INHIBITION DECREASE THE RISK OF SEVERE COVID-19 IN RMD-PATIENTS?

Andreas Krause, U. Müller-Ladner, A. Regierer, 2021, Annals of the Rheumatic Diseases.

Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis?

U. Müller-Ladner, H. Lorenz, R. Voll, 2021, Clinical and experimental rheumatology.

Optimising Patient Management in Rheumatoid Arthritis: Can We Live Up to Patient Expectations?

M. Cerinic, U. Müller-Ladner, T. Thomas, 2019 .

Psychological defensive profile of sciatica patients with neuropathic pain and its relationship to quality of life

U. Müller-Ladner, 2015 .

[Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology - Update 2016].

U. Müller-Ladner, J. Braun, E. Gromnica-ihle, 2017, Zeitschrift fur Rheumatologie.

Gene transfer of protective cytokines in rheumatoid arthritis.

U. Müller-Ladner, R. Gay, S. Gay, 2001, Advances in experimental medicine and biology.

Laser-mediated microdissection as a tool for molecular analysis in arthritis.

U. Müller-Ladner, S. Gay, E. Neumann, 2004, Methods in molecular medicine.

Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis.

P. Petrow, U. Müller-Ladner, K. Moelling, 2004, Arthritis and rheumatism.

Free fatty acids: potential proinflammatory mediators in rheumatic diseases.

U. Müller-Ladner, S. Rehart, E. Neumann, 2015, Annals of the Rheumatic Diseases.

Impact of herbal medicines on physical impairment.

U. Müller-Ladner, S. Chrubasik, A. Black, 2008, Phytomedicine : international journal of phytotherapy and phytopharmacology.

Laser-mediated microdissection for analysis of gene expression in synovial tissue

T. Matsui, U. Müller-Ladner, I. Tarner, 2007, Modern rheumatology.

A 30 year history of panniculitis.

U. Müller-Ladner, O. Distler, K. Palitzsch, 2000, Journal of Rheumatology.

Identification of differentially expressed genes in ileal Peyer's Patch of scrapie-infected sheep using RNA arbitrarily primed PCR

U. Müller-Ladner, I. Olsaker, E. Neumann, 2008, BMC veterinary research.

Persistent inflammation in systemic sclerosis is strongly associated with mortality: a EUSTAR database analysis

A. Gabrielli, U. Müller-Ladner, T. Geiser, 2022, 12.02 - ILD/DPLD of known origin.

Capillaroscopic pattern in paraneoplastic Raynaud’s phenomenon

U. Müller-Ladner, S. Lambova, S. Lambova, 2013, Rheumatology International.

Multimodal physical therapy for treating primary and secondary fibromyalgia – German multimodal rheumatologic complex treatment

U. Müller-Ladner, I. Tarner, U. Lange, 2020, European Journal of Physiotherapy.

[Hand ischemia and increased CRP level in a 75-year-old female patient].

U. Müller-Ladner, D. Librizzi, O. Basten, 2020, Zeitschrift fur Rheumatologie.

Role of nuclear factor kappaB in synovial inflammation.

U. Müller-Ladner, R. Gay, S. Gay, 2002, Current rheumatology reports.

Editorial: Tumor Necrosis Factor–Transgenic Mice: Close Enough to Human Epigenetics?

U. Müller-Ladner, E. Neumann, 2017, Arthritis & rheumatology.

C. Bombardier, C. van Durme, R. Buchbinder, 2014, Annals of the rheumatic diseases.

[Rheumatology 2010].

U. Müller-Ladner, W. Hermann, 2010, Deutsche medizinische Wochenschrift.

Associations between SLC2A9 polymorphisms and gout susceptibility

U. Müller-Ladner, 2017 .

T cell-independent cellular pathways of rheumatoid joint destruction.

U. Müller-Ladner, 1995, Current opinion in rheumatology.

Synovial mast cells require C5a receptor (CD88) for arthritis induction

A. Wunder, U. Müller-Ladner, K. Yudoh, 2003, Arthritis Research & Therapy.

THU0068 COMPARISON OF INFLAMMATION DURING METABOLIC CHANGES IN RHEUMATOID AND OSTEOARTHRITIS MOUSE MODELS

U. Müller-Ladner, G. Schett, E. Neumann, 2020, Annals of the Rheumatic Diseases.

Digital Ulcers in Systemic Sclerosis - How to Manage in 2013?

U. Müller-Ladner, S. Lambova, H. Dobrev, 2013, Current rheumatology reviews.

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus Part 2: Therapy, risk factors and other special topics

Matthias Schneider, U. Müller-Ladner, M. Worm, 2021 .

Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis

M. Kreuter, U. Müller-Ladner, M. Worm, 2023, Rheumatology.

Laser capture as a tool for analysis of gene expression in inflamed synovium.

U. Müller-Ladner, S. Gay, E. Neumann, 2007, Methods in molecular medicine.

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

M. Mayes, M. Baron, D. Furst, 2013, Annals of the rheumatic diseases.

Faculty Opinions recommendation of SNAPIN: an endogenous Toll-like receptor ligand in rheumatoid arthritis.

U. Müller-Ladner, 2012 .

The Pathogenesis of Systemic Sclerosis Revisited

U. Müller-Ladner, M. Geyer, 2011, Clinical reviews in allergy & immunology.

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

E. Feierl, U. Müller-Ladner, J. Morović-Vergles, 2010, Annals of the rheumatic diseases.

Elevated MMP‐7 levels in patients with systemic sclerosis: correlation with pulmonary involvement

M. Hellmich, S. Rosenkranz, U. Müller-Ladner, 2011, Experimental dermatology.

Faculty Opinions recommendation of Resistin, an adipokine with potent proinflammatory properties.

U. Müller-Ladner, 2006 .

Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis.

U. Müller-Ladner, Sabrina Bauer, C. Buechler, 2012, Experimental and molecular pathology.

Free fatty acids: potential proinflammatory mediators in rheumatic diseases.

U. Müller-Ladner, S. Rehart, E. Neumann, 2015, Annals of the rheumatic diseases.

Interferon-α Abrogates the Suppressive Effect of Apoptotic Cells on Dendritic Cells in an In Vitro Model of Systemic Lupus Erythematosus Pathogenesis

U. Müller-Ladner, P. Krammer, H. Lorenz, 2013, The Journal of Rheumatology.

Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern".

U. Müller-Ladner, A. Herrick, C. Denton, 2019, Autoimmunity reviews.

EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cells

A. Gabrielli, U. Müller-Ladner, A. Tyndall, 2018 .

Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis

U. Müller-Ladner, K. Pavelka, S. Gay, 2009, Annals of the rheumatic diseases.

J. D. de Vries-Bouwstra, R. Fischer-Betz, Matthias Schneider, 2021, Clinical and experimental rheumatology.

TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients

M. Humbert, M. Müller-Nurasyid, J. Cracowski, 2012, Annals of the rheumatic diseases.

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)

A. Silman, R. Madhok, K. Chakravarty, 2017, Annals of the rheumatic diseases.

Missing Wrists in a Patient with Rheumatoid Arthritis: A Matter of Compliance

U. Müller-Ladner, F. Wegner, F. Meier, 2017, The Journal of Rheumatology.

Auf dem Weg zur Frühdiagnose der systemischen Sklerose

U. Müller-Ladner, U. Müller‐Ladner, M. Frerix, 2013, Zeitschrift für Rheumatologie.

Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis.

L. Messerini, U. Müller-Ladner, E. Roeb, 2008, Arthritis and rheumatism.

S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

U. Müller-Ladner, F. Moosig, C. Kneitz, 2017, Zeitschrift für Rheumatologie.

Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts

U. Müller-Ladner, S. Gay, T. Pap, 2007, Arthritis research & therapy.

OP0054 Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 48 Data from the Fasscinate Trial

U. Müller-Ladner, C. Denton, J. V. van Laar, 2015 .

Therapeutische Strategien im Frühstadium der systemischen Sklerose

U. Müller-Ladner, W. Hermann, U. Müller‐Ladner, 2013, Zeitschrift für Rheumatologie.

U. Müller-Ladner, S. Visvanathan, H. Kellner, 2019, Annals of the rheumatic diseases.

Rheumatoide Arthritis

U. Müller-Ladner, Dr. E. Decker, 2013, Der Internist.

Side effects and management of side effects of methotrexate in rheumatoid arthritis.

U. Müller-Ladner, K. Albrecht, 2010, Clinical and experimental rheumatology.

Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases.

Matthias Schneider, U. Müller-Ladner, G. Nagy, 2021, Clinical and experimental rheumatology.

Minimum information about a microarray experiment: comment on the editorial by Firestein and Pisetsky.

Oliver Distler, Steffen Gay, Elena Neumann, 2003, Arthritis and rheumatism.

Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!

U. Müller-Ladner, C. Hamm, I. Tarner, 2010, F1000 medicine reports.

A Virtual Reality–Based App to Educate Health Care Professionals and Medical Students About Inflammatory Arthritis: Feasibility Study

U. Müller-Ladner, G. Schett, A. Pfeil, 2021, JMIR serious games.